NDA 022221 · Thea Pharma
Akten
Lidocaine Hydrochloride · Ophthalmic
Last checked: Nov 20, 2026Latest source record: Nov 21, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2008
Oct 7, 2008
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2,569
373 Phase 3, 196 recruiting
FAERS reports
89
69 serious, 4 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 23, 2026.
1- INDICATIONS AND USAGE AKTEN is indicated for ocular surface anesthesia during ophthalmologic procedures in adults and pediatric patients. AKTEN is an amide local anesthetic indicated for ocular surface anesthesia during ophthalmologic procedures. ( 1 )
Mechanism: Lidocaine hydrochloride is an amide local anesthetic agent that stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. Anesthesia generally occurs between 20 seconds to 1 minute and persists for 5 to 30 minutes.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 7, 2008 Original approval · Type 5 - New Formulation or New Manufacturer ReviewSummary ReviewPediatric Medical Review
1 products under this application
- AKTEN · LIDOCAINE HYDROCHLORIDE 3.5% · GEL, OPHTHALMIC · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Lidocaine" as an intervention, any sponsor and status, largest first.
Vanderbilt University Medical CenterAcademic, hospital or other
NCT02726620 · 22,435 participants · Start Jan 5, 2017 · Primary completion Dec 31, 2017
Drug: Propofol; Sevoflurane and 32 more · For: Hypotension
Sites: Nashville, Tennessee
- Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) TrialPivotal-lookingRecruiting
Monash UniversityAcademic, hospital or other
NCT05072314 · 4,300 participants (planned) · Start Jul 27, 2022 · Primary completion May 2028
Drug: lidocaine 2% and 10%; Placebo · For: Breast Cancer; Breast Cancer Female; Breast Conserving Surgery and 1 more
Sites: Kingswood, Australia; Mount Druitt, Australia; Sydney, Australia · 49 sites in all
- Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or TachycardiaPivotal-lookingCompleted
University of WashingtonAcademic, hospital or other
NCT01401647 · 3,024 participants · Start May 2012 · Primary completion Dec 2015
Drug: amiodarone; Lidocaine · For: Cardiac Arrest
Sites: Birmingham, Alabama; San Diego, California; Portland, Oregon · 9 sites in all
- The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac SurgeryPivotal-lookingRecruiting
Vanderbilt University Medical CenterAcademic, hospital or other
NCT07224711 · 2,290 participants (planned) · Start Oct 26, 2026 · Primary completion Oct 31, 2028
Drug: Lidocaine HCl 0.8% in D5W; Dextrose 5% in water · For: Pain; Post Operative Analgesia; Opioid Consumption, Postoperative
Sites: Nashville, Tennessee
- A RCT of Compound Lidocaine Cream to Prevent Postoperative Agitation in Patients With Endotracheal Intubation for GAPivotal-lookingStatus unknown
Third Affiliated Hospital, Sun Yat-Sen UniversityAcademic, hospital or other
NCT02017392 · 2,000 participants (planned) · Start Dec 2013 · Primary completion Mar 2014
Drug: Compound Lidocaine Cream · For: Postoperative Agitation of Patients
Sites: Guangzhou, China
- Anesthesia and Perioperative Neurocognitive Disorders in the Elderly Patients Undergoing Hip Fracture Surgery Platform Trial (ANDES Platform Trial)Pivotal-lookingRecruiting
Second Affiliated Hospital of Wenzhou Medical UniversityAcademic, hospital or other
NCT06452147 · 1,860 participants (planned) · Start Jun 19, 2024 · Primary completion Jul 30, 2028
Drug: Bupivacaine liposome; Regular local anesthetic and 1 more · For: Anesthesia; Hip Fractures; Dementia and 2 more
Sites: Dongyang, China; Hangzhou, China; Jinhua, China · 13 sites in all
First Affiliated Hospital of Harbin Medical UniversityAcademic, hospital or other
NCT06068166 · 1,840 participants · Start Jul 1, 2013 · Primary completion Aug 31, 2019
Drug: GDMT · For: Heart Failure With Reduced Ejection Fraction; Thoracic Epidural Anesthesia
- Evaluation of the Benefit of Lidocaine on the Prevention of the Risk of Post Endoscopic Retrograde Cholangio-pancreatography Pancreatitis.Pivotal-lookingRecruiting
GCS Ramsay Santé pour l'Enseignement et la RechercheAcademic, hospital or other
NCT05667987 · 1,800 participants (planned) · Start Jan 18, 2024 · Primary completion Jan 18, 2026
Drug: Intravenous lidocaine administration · For: ERCP Surgery
Sites: Paris, France
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective14
- local anaesthetic systemic toxicity8
- off label use8
- vision blurred8
- visual acuity reduced8
- overdose7
- hypertension6
- product use in unapproved indication6
- eye pain5
- visual impairment5
- vitreous floaters5
- cystoid macular oedema4
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 2 |
| 2013 | 4 |
| 2014 | 8 |
| 2015 | 1 |
| 2016 | 5 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 7 |
| 2022 | 4 |
| 2023 | 44 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 4 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Akten (Lidocaine HCl/PF)
2024 spending
$2K
Beneficiaries
30
45 claims
Per beneficiary
$63
$17.44 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $1,901 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Adverse effects of articaine versus lidocaine in pediatric dentistry: a meta-analysis.
Li L, Sun DL · J Clin Pediatr Dent 2023 · Meta-Analysis, Systematic Review
- Intravenous lidocaine to prevent postoperative airway complications in adults: a systematic review and meta-analysis.
Yang SS, Wang NN, Postonogova T, et al. · Br J Anaesth 2020 · Meta-Analysis, Systematic Review
- Efficacy of nonopioid analgesics and adjuvants in multimodal analgesia for reducing postoperative opioid consumption and complications in obesity: a systematic review and network meta-analysis.
Carron M, Tamburini E, Linassi F, et al. · Br J Anaesth 2024 · Systematic Review, Network Meta-Analysis
- Evaluating different pain lowering medications during intrauterine device insertion: a systematic review and network meta-analysis.
Samy A, Abbas AM, Mahmoud M, et al. · Fertil Steril 2019 · Systematic Review, Network Meta-Analysis
- Continuous intravenous perioperative lidocaine infusion for postoperative pain and recovery in adults.
Weibel S, Jelting Y, Pace NL, et al. · Cochrane Database Syst Rev 2018 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Lidocaine for preventing postoperative sore throat.
Tanaka Y, Nakayama T, Nishimori M, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Thea Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.